Revenue Growth (YoY)

Catalyst Pharmaceuticals' current revenue growth of 5.6% year-over-year (YoY) means its sales for the most recent fiscal year increased by that percentage compared to the prior year, a common measure of business expansion.

This places it below the healthcare sector median of 6.2%, at the 44th percentile among peer companies, indicating it is growing slower than most of its industry. No trend data is available — the year-over-year change is listed as N/A, the quarter-over-quarter change is N/A, and there are no historical values beyond the single 5.6% figure. Because the metric lacks any directional history, it is impossible to assess whether growth is accelerating or decelerating, leaving the level as the only signal. At 5.6% versus the sector median, the combination of a below-average level with no trend implies neutral investment risk and limited opportunity for outperformance based on revenue momentum alone. This metric directly supports the overall NEUTRAL verdict, as it provides neither a clear positive nor negative signal for the stock.

Frequently Asked Questions

Closest Sector Peers